National Institutes of Health: Carcinoma, Hepatocellular trials

The registry lists 65 Carcinoma, Hepatocellular studies with National Institutes of Health as lead sponsor. 5 are open to participants now and 32 have results posted.

Phase 1 17Phase 2 41Phase 3 2Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Vanguard Study: Testing a New Way to Screen for CancerRecruitingNCT06995898Not applicable
• Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE TrialRecruitingNCT06811116Phase 1/2
• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruitingNCT06503146Phase 2
• A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitingNCT06066138Phase 1
• GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesRecruitingNCT05003895Phase 1
• 18F-DCFPyL PET/CT in Hepatocellular CarcinomaTerminatedNCT05009979Phase 2Results posted
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results posted
• Electromagnetic Tracking and Optical Imaging With ICG for Hepatic BiopsiesTerminatedNCT04258566Not applicableResults posted
• Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the LiverActive, not recruitingNCT04175912Phase 2Results posted
• Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic CancersTerminatedNCT03785210Phase 2Results posted
• Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous CancerTerminatedNCT03480152Phase 1/2Results posted
• Simvastatin in Preventing Liver Cancer in Patients With Liver CirrhosisCompletedNCT02968810Phase 2Results posted
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
• A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)CompletedNCT02821754Phase 2Results posted
• LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic TumorsTerminatedNCT02649868Not applicableResults posted
• Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the LiverCompletedNCT02273362Phase 1/2Results posted
• Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by SurgeryCompletedNCT02042443Phase 2Results posted
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing CancerCompletedNCT01967823Phase 2Results posted
• Tremelimumab With Chemoembolization or Ablation for Liver CancerCompletedNCT01853618Phase 1/2Results posted
• Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid CancerCompletedNCT01502410Phase 2Results posted
• MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by SurgeryCompletedNCT01425879Phase 2Results posted
• TRC105 for Liver Cancer That Has Not Responded to SorafenibCompletedNCT01375569Phase 2Results posted
• Sorafenib and TRC105 in Hepatocellular CancerCompletedNCT01306058Phase 1/2Results posted
• MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous TherapyTerminatedNCT01239355Phase 2Results posted
• Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT01015833Phase 3Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by SurgeryCompletedNCT01004978Phase 3Results posted
• IMC-A12 in Treating Patients With Advanced Liver CancerCompletedNCT00639509Phase 2Results posted
• Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT00604721Phase 2Results posted
• Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by SurgeryTerminatedNCT00459108Phase 2Results posted
• AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver CancerTerminatedNCT00427973Phase 2Results posted
• Bevacizumab and Erlotinib in Treating Patients With Advanced Liver CancerCompletedNCT00365391Phase 2Results posted
• Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT00321594Phase 1/2Results posted
• Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract CancerCompletedNCT00107536Phase 2Results posted
• Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT00101036Phase 2Results posted
• Doxorubicin and Bortezomib in Treating Patients With Liver CancerCompletedNCT00083226Phase 2Results posted
• Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver CancerCompletedNCT00055692Phase 2Results posted
• Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing SurgerySuspendedNCT04955808
• National Translational Science Network of Precision-based Immunotherapy for Primary Liver CancerCompletedNCT04145141
• Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) OralWithdrawnNCT04025567Phase 2
• Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract CarcinomaActive, not recruitingNCT03937830Phase 2
• Natural History Study of Children and Adults With Fibrolamellar Hepatocellular CarcinomaWithdrawnNCT03748927
• People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral AgentsActive, not recruitingNCT03520660Phase 4
• Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver DysfunctionWithdrawnNCT03217253Phase 1
• DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus InfectionActive, not recruitingNCT02772003Phase 1
• Gut Microbiota in People With Hepatocellular Carcinoma (HCC)WithdrawnNCT02599909
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT02143401Phase 1
• Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver CancerCompletedNCT01008566Phase 1
• A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore AreaCompletedNCT00913757
• Long-term Follow-up of HALT-C Sustained Virological RespondersCompletedNCT00825877
• Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
• The Second Multicenter Hemophilia Cohort StudyCompletedNCT00341705
• Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT00238394Phase 2
• Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00077441Phase 2
• Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00071994Phase 2
• Oxaliplatin in Treating Patients With Liver CancerCompletedNCT00052364Phase 2
• Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver DysfunctionCompletedNCT00047346Phase 1
• Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically RemovedTerminatedNCT00047333Phase 2
• Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder CancerCompletedNCT00033462Phase 2
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• BMS-247550 in Treating Patients With Liver or Gallbladder CancerTerminatedNCT00023946Phase 2
• Treatment of Hepatocellular Carcinoma With TetrathiomolybdateCompletedNCT00006332Phase 2
• Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by SurgeryCompletedNCT00006016Phase 2